New Takeda, Karolinska Collaboration to Identify Clinical Targets in IBD

New Takeda, Karolinska Collaboration to Identify Clinical Targets in IBD
A new collaboration to identify and validate clinical targets in inflammatory bowel disease (IBD) was recently announced by Japan’s Takeda Pharmaceutical Company, Sweden’s Karolinska Institutet, and the Structural Genomics Consortium,  a public-private charity. The collaboration involves the creation of a translational medicine research team with scientists and clinicians from Takeda, Karolinska University Hospital, and SGC. The

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *